En Carta Diagnostics Raises €1.5M for Lyme Disease Diagnostic Kit Development

En Carta Diagnostics' Pre-Seed Funding

Key Highlights:

• Pre-Seed Funding: En Carta Diagnostics, a Paris-based startup, raised €1.5M in funding.
• Diagnostic Kit Development: Funds will be used to develop a diagnostic kit for autonomously detecting Lyme disease within minutes.
• Point-of-Care Diagnostic Platform: En Carta provides a rapid diagnostic platform using aptamers in a frugal cassette format, enabling a wide range of applications.

En Carta Diagnostics' Target Market

• Medical Professionals: Healthcare providers, doctors, and clinics specializing in diagnosing and treating Lyme disease.
• Public Health Agencies: Organizations focused on monitoring and controlling vector-borne diseases, including Lyme disease.
• Research Institutions: Institutions conducting research on Lyme disease and other genetic, pathogenic, or veterinary indications.

What En Carta Diagnostics Needs to Buy

• Research and Development Services: Collaborating with research organizations and experts in molecular diagnostics to further develop their diagnostic kit.
• Manufacturing and Supply Chain Solutions: Partnering with manufacturers to produce and distribute their diagnostic kits.
• Marketing and Sales Support: Engaging with marketing agencies and sales experts to effectively promote and distribute their diagnostic kits.